Goldman Sachs
APRE icon

Goldman Sachs’s Aprea Therapeutics APRE Stock Holding History

Goldman Sachs’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,455
Closed -$54K – 6442
2022
Q1 		$54K Buy
1,455
+264
+22% +$10.8K ﹤0.01% 6252
2021
Q4 		$68K Sell
1,191
-6,047
-84% -$534K ﹤0.01% 6211
2021
Q3 		$740K Buy
7,238
+4,111
+131% +$373K ﹤0.01% 4955
2021
Q2 		$305K Sell
3,127
-528
-14% -$48.8K ﹤0.01% 5512
2021
Q1 		$373K Buy
+3,655
New +$426K ﹤0.01% 5308
2020
Q4 		– Sell
-1,653
Closed -$795K – 5466
2020
Q3 		$795K Buy
1,653
+304
+23% +$170K ﹤0.01% 4232
2020
Q2 		$1.05M Buy
1,349
+745
+123% +$489K ﹤0.01% 3914
2020
Q1 		$420K Buy
+604
New +$443K ﹤0.01% 4313

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Goldman Sachs's APRE Position: Q2 2022 in Review

Goldman Sachs sold out of Aprea Therapeutics (APRE) in Q2 2022, closing a stake of 1,455 shares — an estimated $54K sold.

Goldman Sachs first reported a position in APRE in Q1 2020 and held it in 8 quarters. The position peaked at $1.05M in Q2 2020. 33 funds tracked by Wall St. Rank hold APRE as of Q2 2022.

  • Goldman Sachs reported no remaining Aprea Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 1,455 Aprea Therapeutics shares in Q2 2022, an estimated $54K.
  • Goldman Sachs first reported a position in Aprea Therapeutics in Q1 2020 and held it in 8 quarters.
  • Goldman Sachs's Aprea Therapeutics position peaked at $1.05M in Q2 2020.
  • 33 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.